DOCSLIB.ORG

1 LEARNING OBJECTIVES What Is Epilepsy??

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 LEARNING OBJECTIVES What Is Epilepsy?? John Doe, M.D. / OUHSC Neurology THE TITLE OF MY TALK Anti-Epileptic Drugs: Seizures, Spells, & Side Effects Juliane Chainakul, APRN-CNS, CDE Clinical Instructor, Epilepsy, General Neurology Department of Neurology The University of Oklahoma Health Sciences Center OU Neurology LEARNING OBJECTIVES Describe seizure classification Discuss pharmacological treatment of seizures Describe common side effects of AEDs Describe common drug-drug interactions of AEDs OU Neurology What is epilepsy?? Epilepsy is the 4th most common neurological problem. 2.9 million American adults and children live with epilepsy 1 in 26 people in the US will have epilepsy at some point in their life. 1 in 10 Americans will have a seizure. Epilepsy costs the US about $15.5 billion in healthcare and other expenses. The Epilepsy Foundation. www.epilepsy.com OU Neurology 1 John Doe, M.D. / OUHSC Neurology THE TITLE OF MY TALK What is epilepsy? Epilepsy is a chronic brain disorder of various causes characterized by recurrent, unprovoked seizures due to abnormal electrical activity in the brain. Seizure is a symptom of epilepsy. The seizure features depend on the area of brain involved. OU Neurology Common Causes of New Onset Seizures Benign febrile convulsions of childhood Idiopathic/cryptogenic seizures Cerebral dysgenesis Symptomatic epilepsy ◦ Head trauma ◦ Stroke / vascular malformations ◦ Mass lesions ◦ CNS infections: encephalitis, meningitis, cysticercosis, HIV encelphalopathy Sydor & Edmondson, 2012 OU Neurology Seizure types 1. Red: Seizure focus. Simple partial seizure = aura. 2. Yellow: Complex partial seizure. 3. Green: Secondary generalized seizure. Blue: Primary generalized seizure. OU Neurology 2 John Doe, M.D. / OUHSC Neurology THE TITLE OF MY TALK ILAE epilepsy classifications OU Neurology Not all seizures are epilepsy About 1/3 of EMU patients have the diagnosis of non-epileptic spell (psychogenic or pseudoseizure). OU Neurology Evaluation Diagnosis: Clinical history General physical exam, neurological exam Lab: CBC, CMP, Ca+, renal, hepatic Supporting/confirmatory studies: EEG CT head MRI brain OU Neurology 3 John Doe, M.D. / OUHSC Neurology THE TITLE OF MY TALK Electroencephalogram (EEG) EEG is the most important neurophysiological study for the diagnosis, prognosis, and treatment of epilepsy. Graphical depiction of cortical electrical activity, usually recorded from the scalp Activation Procedures ◦ Sleep deprivation, photic stimulation, hyperventilation OU Neurology OU Neurology Epilepsy Treatment AEDs Neuromodulation: ◦ Vagal Nerve Stimulation ◦ Deep Brain Stimulation ◦ Responsive neurostimulation device Diet Surgery OU Neurology 4 John Doe, M.D. / OUHSC Neurology THE TITLE OF MY TALK History of antiepileptic drug therapy in the U.S. 1857 - bromides 1993 – felbamate, gabapentin 1912 – phenobarbital 1995 – lamotrigine 1937 – phenytoin 1997 – topiramate, tiagabine 1999 – levetiracetam 1944 - trimethodione 2000 – oxcarbazepine, 1954 - primidone zonisamide 1960 - ethosuximide 2005 - pregabalin 1974 – carbamazepine 2009 – lacosamide, vigabatrin, rufinamide 1975 – clonazepam 2011- ezogabine, clobazam 1978 – valproate 2013- perampanel, eslicarbazepine OU Neurology Epilepsy treatment - AEDs Anti-epileptic drugs (AED) are the first- line of treatment. ◦ There are 20+ AEDs now. ◦ Only treats seizure (symptom), but not the underlying epilepsy 60-70% of people with epilepsy have well controlled seizures with 1-2 AEDs. 30-40% fail medical therapy and become “medically intractable”. OU Neurology Goal Best seizure control, with the least amount of medication,with the least side effects. OU Neurology 5 John Doe, M.D. / OUHSC Neurology THE TITLE OF MY TALK Choosing Anti-Epileptic Drugs (AEDs) Drug effectiveness for the seizure type/ classification Potential adverse effects Interactions with other AEDs and non-AED medications Medical co-morbidities Age, gender, and child-bearing plans Lifestyle and patient preference Cost Rational polypharmacy OU Neurology AEDs by efficacy Broad-Spectrum Narrow-Spectrum valproate carbamazepine clonazepam oxcarbazepine lamotrigine gabapentin levetiracetam pregabalin topiramate phenobarbital zonisamide primidone* felbamate* tiagabine clobazam* eslicarbazepine Unclear spectrum: viagabatrin* - Phenytoin ethosuximide - lacosamide, rufinamide* - Ezogabine* - perampanel* OU Neurology AED Mechanisms of Action Continuum, 2013 OU Neurology 6 John Doe, M.D. / OUHSC Neurology THE TITLE OF MY TALK Continuum,OU Neurology2013 Continuum, 2013 OU Neurology Common side effects of AEDs Sedation Dizziness Fatigue Nausea Vomiting Cognitive impairment Visual changes Behavior changes: depression/mood OU Neurology 7 John Doe, M.D. / OUHSC Neurology THE TITLE OF MY TALK Phenobarbital Has been in clinical use since 1912 as sedative and sleep aid First line therapy for infants only. Used infrequently as first line in adults Effective against focal and generalized tonic-clonic seizures but not effective against generalized absence seizures. Can be used in the treatment of status epilepticus OU Neurology Phenobarbital MOA: y-aminobutyric acid (GABA)-A receptor, prolonging the opening of the associated chloride channel Long half-life of 80-100 hours Potent hepatic P450 enzyme inducer, accelerating the metabolism of medications processed by this enzyme system and reducing their plasma concentration. (so it may render concomitant AEDs less effective if they are metabolized by the liver.) OU Neurology Phenobarbital Starting maintenance dose: Start low 30-60mg at bedtime. 1mg/kg/d to 2.5mg/kg/day. Increase dose by 30mg q 2 weeks as needed Adverse side effects: Sedation, decreased concentration, and mood changes. ◦ Long term use: decreased bone density and connective tissue effects; Dupuytren contractures, plantar fibromatosis, and frozen shoulder Pregnancy Category D: Teratogenicity with increased risk of cardiac malformations, decreased cognitive abilities OU Neurology 8 John Doe, M.D. / OUHSC Neurology THE TITLE OF MY TALK Unclear Efficacy Phenytoin (Dilantin) Been in clinical use since 1938 Efficacy against focal and GTC. Not effective against generalized myoclonic or generalized absence seizures and may even exacerbate AVOID in idiopathic generalized epilepsy Binds to the active state of the sodium channel to prolong its fast inactivated state, thus reducing the high- frequency firing as might occur during a seizure, while allowing normal action potentials to occur Highly protein bound Metabolized by liver, cytochrome P450, 2C9, and CYP 2C19 OU Neurology Phenytoin Bioavailability is reduced with calcium, antacids, and NG tube feedings Potent enzyme inducer that reduces the efficacy of drugs metabolized by the P450 enzyme system Agents that reduce its metabolism and cause it to accumulate: Amiodarone, fluoxetine, fluvoxamine, isoniazid, and azole anti-fungal agents The PHY protein-free fraction may increase with hepatic and renal failure, in low-protein states, during pregnancy, elderly, and in presence of highly protein- bound drugs such as valproate OU Neurology Phenytoin Dosing: 200mg-400mg/day at bedtime, ER preferred Therapeutic serum concertation range: 10-20mg/L Protein-free levels 1mg – 2mg/L Fosphenytoin – prodrug available for IV/IM. Water soluble, better tolerated and absorbed; ◦ 20mgPE/kg IV-- hypotension and arrhythmias Adverse effects: less sedating than PHB, cognitive effects, ataxia, incoordination, dysarthria, nystagmus, and diplopia. Rash, Stevens-Johnson syndrome with fever, rash, lymphadenopathy, eosinophilia, liver/renal Chronic use: Gingival hyperplasia, acne, hirsutism, cerebellar atrophy, decreased bone density, anemia, and peripheral neuropathy OU Neurology 9 John Doe, M.D. / OUHSC Neurology THE TITLE OF MY TALK Valproate, divalproex, valproic acid (Depakote, Depacon) Broad spectrum – focal and generalized FDA indication also for migraine prophylaxis and bipolar disorder Most effective AED for idiopathic generalized epilepsy with GTC ◦ First choice for men with generalized epilepsy MOA: GABA potentiation, blocking of T-Type calcium changes, blocking of sodium channels Highly protein bound at 90% ◦ The free faction increases with increasing total concentration and with coadministration of phenytoin, with which it competes for protein binding OU Neurology Valproate (Depakote, Depacon) Potent inhibitor – reducing the clearance of phenobarbital lamotrigine, rufinamide, and carbamazepine epoxide Dosing: 500mg at bedtime for divalproate ER or 250mg bid for the delayed and immediate release. Increased up to 1000 (for woman of child-bearing age)- 2000mg/day Therapeutic range: 50-100mg/L OU Neurology Valproate (Depakote, Depacon) Adverse effects: tremor, weight gain, hair loss, peripheral edema, thrombocytopenia, liver toxicity, hyperammonemia Rare: idiosyncratic hepatotoxicity & pancreatitis Highest rate of teratogenicity among antiepileptic drugs and should be avoided in women of child bearing age. OU Neurology 10 John Doe, M.D. / OUHSC Neurology THE TITLE OF MY TALK Lamotrigine (Lamictal, Lamictal XR) Broad spectrum with FDA indications for focal seizures, generalized tonic-clonic seizures, and Lennox-Gastaux syndrome. ◦ Not as effective against generalized absence seizures It can be effective for myoclonic seizures but can also worsen them in others FDA indication for maintenance treatment in bipolar I disorder MOA: blocks sodium channels like phenytoin and carbamazepine OU Neurology Lamotrigine Estrogen and pregnancy
Load more

Recommended publications
  • “Seizure Disorders” January 2017 This Is the Beginning of CE PRN’S 39Th Year
    Pharmacy Continuing Education from WF Professional Associates ABOUT WFPA LESSONS TOPICS ORDER CONTACT PHARMACY EXAM REVIEWS “Seizure Disorders” January 2017 This is the beginning of CE PRN’s 39th year. WOW! Thanks for your continued participation. The primary goal of seizure disorder treatment is to achieve a seizure-free patient. We update this topic often because it’s so important. This lesson provides 1.25 (0.125 CEUs) contact hours of credit, and is intended for pharmacists & technicians in all practice settings. The program ID # for this lesson is 0798-000-18-228-H01-P for pharmacists & 0798-000-18-228-H01-T for technicians. Participants completing this lesson by December 31, 2019 may receive full credit. Release date for this lesson is January 1, 2017. To obtain continuing education credit for this lesson, you must answer the questions on the quiz (70% correct required), and return the quiz. Should you score less than 70%, you will be asked to repeat the quiz. Computerized records are maintained for each participant. If you have any comments, suggestions or questions, contact us at the above address, or call 1-843-488-5550. Please write your name, NABP eProfile (CPE Monitor®) ID Number & birthdate (MM/DD) in the indicated space on the quiz page. The objectives of this lesson are such that upon completion participants will be able to: Pharmacists: Technicians: 1. Describe the epidemiology of seizure disorders. 1. List the types of seizures. 2. List the types of seizures. 2. List factors that affect the selection of 3. Discuss the goals associated with treating seizure anticonvulsants.
    [Show full text]
  • Daniel Hussar, Phd, New Drug Update
    New Drug Update 2014* *Presentation by Daniel A. Hussar, Ph.D. Remington Professor of Pharmacy Philadelphia College of Pharmacy University of the Sciences in Philadelphia Objectives: After attending this program, the participant will be able to: 1. Identify the indications and routes of administration of the new therapeutic agents. 2. Identify the important pharmacokinetic properties and the unique characteristics of the new drugs. 3. Identify the most important adverse events and precautions of the new drugs. 4. Compare the new drugs to the older therapeutic agents to which they are most similar in activity. 5. Identify information regarding the new drugs that should be communicated to patients. New Drug Comparison Rating (NDCR) system 5 = important advance 4 = significant advantage(s) (e.g., with respect to use/effectiveness, safety, administration) 3 = no or minor advantage(s)/disadvantage(s) 2 = significant disadvantage(s) (e.g., with respect to use/effectiveness, safety, administration) 1 = important disadvantage(s) Additional information The Pharmacist Activist monthly newsletter: www.pharmacistactivist.com Dapagliflozin propanediol (Farxiga – Bristol-Myers Squibb; AstraZeneca) Antidiabetic Agent 2014 New Drug Comparison Rating (NDCR) = Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Comparable drug: Canagliflozin (Invokana) Advantages: --May be less likely to cause hypersensitivity reactions and hyperkalemia --May be less likely to interact with other medications --May
    [Show full text]
  • Caffeine Posited to Enhance Psoriasis Tx Response
    30 Skin Disorders FAMILY P RACTICE N EWS • July 1, 2006 Caffeine Posited to Enhance Psoriasis Tx Response BY ERIK GOLDMAN versity of Michigan, Ann Arbor. The im- flammatory, and they work by inhibiting drinkers were more likely to discontinue Contributing Writer pact of coffee and other caffeine-containing an enzyme called 5-amidoimidazole-4-car- MTX therapy due to perceived lack of ef- beverages on inflammatory conditions such boxamide ribonucleotide (AICAR) trans- ficacy. A second rheumatoid arthritis study P HILADELPHIA — Patients with psori- as psoriasis has been the subject of con- formylase, resulting in AICAR accumula- involving 39 patients also showed inhibi- asis who drink coffee frequently respond troversy for some time. Many people con- tion. This leads to increased adenosine tion of the drug’s effects, but other pub- better to treatment with methotrexate sider caffeine to be proinflammatory and which has anti-inflammatory properties,” lished studies show no such effects. and sulfasalazine, Dr. Yolanda Helfrich re- have suggested that patients with inflam- explained Dr. Helfrich. “Caffeine acts as an But it appears that, at least biochemi- ported at the annual meeting of the Soci- matory diseases cut their consumption. adenosine receptor antagonist, so you’d cally, coffee has bivalent effects. While it is ety for Investigative Dermatology. On face value, one would expect coffee expect it to inhibit MTX and SSZ.” true that caffeine is an adenosine receptor That should be good news for patients to thwart the efficacy of drugs such as Indeed, a study published several years antagonist, it also increases cyclic adeno- who like to drink coffee, said Dr.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • A Textbook of Clinical Pharmacology and Therapeutics This Page Intentionally Left Blank a Textbook of Clinical Pharmacology and Therapeutics
    A Textbook of Clinical Pharmacology and Therapeutics This page intentionally left blank A Textbook of Clinical Pharmacology and Therapeutics FIFTH EDITION JAMES M RITTER MA DPHIL FRCP FMedSci FBPHARMACOLS Professor of Clinical Pharmacology at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK LIONEL D LEWIS MA MB BCH MD FRCP Professor of Medicine, Pharmacology and Toxicology at Dartmouth Medical School and the Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA TIMOTHY GK MANT BSC FFPM FRCP Senior Medical Advisor, Quintiles, Guy's Drug Research Unit, and Visiting Professor at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK ALBERT FERRO PHD FRCP FBPHARMACOLS Reader in Clinical Pharmacology and Honorary Consultant Physician at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK PART OF HACHETTE LIVRE UK First published in Great Britain in 1981 Second edition 1986 Third edition 1995 Fourth edition 1999 This fifth edition published in Great Britain in 2008 by Hodder Arnold, an imprint of Hodden Education, part of Hachette Livre UK, 338 Euston Road, London NW1 3BH http://www.hoddereducation.com ©2008 James M Ritter, Lionel D Lewis, Timothy GK Mant and Albert Ferro All rights reserved. Apart from any use permitted under UK copyright law, this publication may only be reproduced, stored or transmitted, in any form, or by any means with prior permission in writing of the publishers or in the case of reprographic production in accordance with the terms of licences issued by the Copyright Licensing Agency.
    [Show full text]
  • Identification of Human Sulfotransferases Involved in Lorcaserin N-Sulfamate Formation
    1521-009X/44/4/570–575$25.00 http://dx.doi.org/10.1124/dmd.115.067397 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:570–575, April 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Identification of Human Sulfotransferases Involved in Lorcaserin N-Sulfamate Formation Abu J. M. Sadeque, Safet Palamar,1 Khawja A. Usmani, Chuan Chen, Matthew A. Cerny,2 and Weichao G. Chen3 Department of Drug Metabolism and Pharmacokinetics, Arena Pharmaceuticals, Inc., San Diego, California Received September 30, 2015; accepted January 7, 2016 ABSTRACT Lorcaserin [(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benza- and among the SULT isoforms SULT1A1 was the most efficient. The zepine] hydrochloride hemihydrate, a selective serotonin 5-hydroxy- order of intrinsic clearance for lorcaserin N-sulfamate is SULT1A1 > Downloaded from tryptamine (5-HT) 5-HT2C receptor agonist, is approved by the U.S. SULT2A1 > SULT1A2 > SULT1E1. Inhibitory effects of lorcaserin Food and Drug Administration for chronic weight management. N-sulfamate on major human cytochrome P450 (P450) enzymes Lorcaserin is primarily cleared by metabolism, which involves were not observed or minimal. Lorcaserin N-sulfamate binds to multiple enzyme systems with various metabolic pathways in human plasma protein with high affinity (i.e., >99%). Thus, despite humans. The major circulating metabolite is lorcaserin N-sulfamate. being the major circulating metabolite, the level of free lorcaserin Both human liver and renal cytosols catalyze the formation of N-sulfamate would be minimal at a lorcaserin therapeutic dose and lorcaserin N-sulfamate, where the liver cytosol showed a higher unlikely be sufficient to cause drug-drug interactions.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • GLUOCXEOGENIC ENZYMES* Neogenic Processes. The
    96 BIOCHEMISTRY: WEBER ET AL. PROC. N. A. S. tion yielded products which competitively inhibited the aminoacylation of native sRNA. The inhibition was specific for a given amino acid acceptor. Periodate oxidation of preparations enriched in tyrosyl-sRNA and poor in valyl-sRNA yielded an inhibitor effective in the tyrosine system and ineffective in the valine system. Similar specificity was observed with a periodate-treated fraction which had been enriched in valine acceptor activity. * USPHS postdoctoral International Fellow; Fellow del Instituto Nacional de la Investigacion Cientifica de Mexico. 1 Chapeville, F., F. Lipmann, G. von Ehrenstein, B. Weisblum, W. J. Ray, Jr., and S. Benzer, these PROCEEDINGS, 48, 1086 (1962). 2 Bergmann, F. H., P. Berg, and M. Dieckmann, J. Biol. Chem., 236, 1735 (1961). 3 Apgar, J., R. W. Holley, and S. H. Merrill, J. Biol. Chem., 237, 796 (1962). 4 Berg, P., F. H. Bergmann, E. J. Ofengand, and M. Dieckmann, J. Biol. Chem., 236, 1726 (1961). 6 Zubay, G., and M. Takanami, Biochem. Biophys. Res. Commun., 15, 207 (1964). 6Nihei, T., and G. L. Cantoni, J. Biol. Chem., 238, 3991 (1963). 7 Holley, R. W., J. Apgar, B. P. Doctor, J. Farrow, M. A. Marini, and S. H. Merrill, J. Biol. Chem., 236, 200 (1961). 8 Preiss, J., P. Berg, E. J. Ofengand, F. H. Bergmann, and M. Dieckmann, these PROCEEDINGS, 45, 319 (1959). 9 Whitfeld, P. R., and R. Markham, Nature, 171, 1151 (1953). 10 Lineweaver, H., and D. Burk, J. Am. Chem. Soc., 56, 658 (1934). 11 A comparison of the products of a 4% digestion with snake venom by the two procedures showed that the capacity to accept valine was reduced to about 1% by the technique of Zubay and Takanami (ref.
    [Show full text]
  • Local Anesthetics
    Local Anesthetics Introduction and History Cocaine is a naturally occurring compound indigenous to the Andes Mountains, West Indies, and Java. It was the first anesthetic to be discovered and is the only naturally occurring local anesthetic; all others are synthetically derived. Cocaine was introduced into Europe in the 1800s following its isolation from coca beans. Sigmund Freud, the noted Austrian psychoanalyst, used cocaine on his patients and became addicted through self-experimentation. In the latter half of the 1800s, interest in the drug became widespread, and many of cocaine's pharmacologic actions and adverse effects were elucidated during this time. In the 1880s, Koller introduced cocaine to the field of ophthalmology, and Hall introduced it to dentistry Overwiev Local anesthetics (LAs) are drugs that block the sensation of pain in the region where they are administered. LAs act by reversibly blocking the sodium channels of nerve fibers, thereby inhibiting the conduction of nerve impulses. Nerve fibers which carry pain sensation have the smallest diameter and are the first to be blocked by LAs. Loss of motor function and sensation of touch and pressure follow, depending on the duration of action and dose of the LA used. LAs can be infiltrated into skin/subcutaneous tissues to achieve local anesthesia or into the epidural/subarachnoid space to achieve regional anesthesia (e.g., spinal anesthesia, epidural anesthesia, etc.). Some LAs (lidocaine, prilocaine, tetracaine) are effective on topical application and are used before minor invasive procedures (venipuncture, bladder catheterization, endoscopy/laryngoscopy). LAs are divided into two groups based on their chemical structure. The amide group (lidocaine, prilocaine, mepivacaine, etc.) is safer and, hence, more commonly used in clinical practice.
    [Show full text]
  • Potentially Hazardous Drug Interactions with Psychotropics Ben Chadwick, Derek G
    Chadwick et al Advances in Psychiatric Treatment (2005), vol. 11, 440–449 Potentially hazardous drug interactions with psychotropics Ben Chadwick, Derek G. Waller and J. Guy Edwards Abstract Of the many interactions with psychotropic drugs, a minority are potentially hazardous. Most interactions are pharmacodynamic, resulting from augmented or antagonistic actions at a receptor or from different mechanisms in the same tissue. Most important pharmacokinetic interactions are due to effects on metabolism or renal excretion. The major enzymes involved in metabolism belong to the cytochrome P450 (CYP) system. Genetic variation in the CYP system produces people who are ‘poor’, ‘extensive’ or ‘ultra-rapid’ drug metabolisers. Hazardous interactions more often result from enzyme inhibition, but the probability of interaction depends on the initial level of enzyme activity and the availability of alternative metabolic routes for elimination of the drug. There is currently interest in interactions involving uridine diphosphate glucuronosyltransferases and the P-glycoprotein cell transport system, but their importance for psychotropics has yet to be defined. The most serious interactions with psychotropics result in profound sedation, central nervous system toxicity, large changes in blood pressure, ventricular arrhythmias, an increased risk of dangerous side-effects or a decreased therapeutic effect of one of the interacting drugs. A drug interaction, defined as the modification of habits, problems related to polypharmacy are likely the action of one drug by another, can be beneficial to grow. or harmful, or it can have no significant effect. An There are numerous known and potential inter- appreciation of clinically important interactions is actions with psychotropic drugs, and many of them becoming increasingly necessary with the rising use do not have clinically significant consequences.
    [Show full text]
  • A Comprehensive Guide Ram Roth Elizabeth A.M. Frost Clifford Gevirtz
    The Role of Anesthesiology in Global Health A Comprehensive Guide Ram Roth Elizabeth A.M. Frost Cli ord Gevirtz Editors Carrie L.H. Atcheson Associate Editor 123 The Role of Anesthesiology in Global Health Ram Roth • Elizabeth A.M. Frost Clifford Gevirtz Editors Carrie L.H. Atcheson Associate Editor The Role of Anesthesiology in Global Health A Comprehensive Guide Editors Ram Roth Elizabeth A.M. Frost Department of Anesthesiology Department of Anesthesiology Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai New York , NY , USA New York , NY , USA Clifford Gevirtz Department of Anesthesiology LSU Health Sciences Center New Orleans , LA , USA Associate Editor Carrie L.H. Atcheson Oregon Anesthesiology Group Department of Anesthesiology Adventist Medical Center Portland , OR , USA ISBN 978-3-319-09422-9 ISBN 978-3-319-09423-6 (eBook) DOI 10.1007/978-3-319-09423-6 Springer Cham Heidelberg New York Dordrecht London Library of Congress Control Number: 2014956567 © Springer International Publishing Switzerland 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.
    [Show full text]